TRIM27 and ovarian cancer: The 5-year overall survival (OS) curve of the ovarian cancer patients with respect to RFP expression showed a trend toward poor prognosis for the patients with positive RFP immunoreactivity, although it was not statistically significant (P = 0.1266, Fig. 1B).